The project will focus its activities on three priority virus groups, responsible of major human viral diseases for which the development of drugs is considered essential: flaviviridae (Dengue), picornaviridae (enterovirus 71) and paramyxoviridae (RCV and hMPV). On the other hand, exploratory researches will be performed on other virus families that have the potential to cause epidemics, like the arenaviruses group, alphaviruses, bunyaviruses, coronaviruses and noroviruses .
The SILVER project contains 6 work packages.
The objectives of WP3 are:
- to discover compounds with antiviral activity (“hits”) against isolated enzymes of dengue virus, one or more enterovirus(es), one paramyxovirus, and one or more emerging virus(es) from another group.
- to optimize the most promising of these hits (as well as those identified by cell-based screening in WP1) through medicinal chemistry (including structure-based synthetic chemistry) and turn them into lead candidates.
- to develop and deploy methods (in particular, for fragment-based design) in X-ray crystallography, STD-NMR spectroscopy, and fragment-ligation chemistry.
- to deliver antiviral compounds to WP4 for preliminary evaluation in animal models.